Executive · Scientist · Operator
Jerry McMahon
Dr. Jerry McMahon is the President and CEO of STORM Therapeutics, a Cambridge, UK biotech pioneering drugs that target RNA modifying enzymes. A biochemist-turned-operator with more than 30 years in oncology drug development, he has led biotechs from bench to IPO, helped bring the cancer drug sunitinib (Sutent) to patients, and now steers STORM's first-in-class METTL3 inhibitor STC-15 through the clinic - the first RNA modification enzyme inhibitor ever to enter human trials.